Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | Mr. Dion J. WeislerIndependent Director | -80,29 | 36,27k | Sale to Issuer | 451,79 | 4,95k | -1,60% |
| 2026-04-27 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400,00 | 185,06k | Automatic Disposition | 462,66 | 25,05k | -1,57% |
| 2026-03-11 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -1,61k | 802,54k | Automatic Disposition | 499,40 | 18,32k | -8,06% |
| 2026-03-05 | Mr. Marc N. CasperChairman & CEO | -4,00k | 820,74k | Derivative Exercise and Sale | 309,63 - 519,74 | 141,91k | - |
| 2026-03-03 | Mr. Marc N. CasperChairman & CEO | -10,00k | 1,98M | Derivative Exercise and Sale | 309,63 - 516,75 | 141,91k | - |
| 2026-02-28 | Mr. Marc N. CasperChairman & CEO | -4,68k | 2,44M | Sale to Issuer | 521,11 | 141,91k | -3,20% |
| 2026-02-28 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -348,08 | 181,39k | Sale to Issuer | 521,11 | 13,33k | -2,54% |
| 2026-02-28 | Mr. Joseph R. HolmesVP & CAO | -116,63 | 60,77k | Sale to Issuer | 521,11 | 2,52k | -4,42% |
| 2026-02-28 | Mr. Michel LagardeInsider | -1,20k | 623,56k | Sale to Issuer | 521,11 | 85,15k | -1,39% |
| 2026-02-28 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -1,07k | 559,35k | Sale to Issuer | 521,11 | 25,45k | -4,05% |
| 2026-02-28 | Mr. Stephen WilliamsonInsider | -921,79 | 480,36k | Sale to Issuer | 521,11 | 45,17k | -2,00% |
| 2026-02-28 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -815,85 | 425,15k | Sale to Issuer | 521,11 | 19,93k | -3,93% |
| 2026-02-28 | Mr. Frederick M. LoweryInsider | -896,97 | 467,42k | Sale to Issuer | 521,11 | 13,46k | -6,25% |
| 2026-02-09 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400,00 | 216,48k | Automatic Disposition | 541,20 | 20,75k | -1,89% |
| 2025-12-10 | Mr. Scott M. SperlingIndependent Lead Director | -4,39k | 0,00 | Other Disposition | - | 68,42k | -6,02% |
| 2025-12-04 | Mr. Michel LagardeInsider | 18,64k | 1,96M | Derivative Exercise and Retained Stock | 105,17 | 84,12k | 28,46% |
| 2025-12-04 | Mr. Michel LagardeInsider | -22,05k | 9,50M | Derivative Exercise and Sale | 132,66 - 563,56 | 84,12k | - |
| 2025-12-02 | Mr. Michel LagardeInsider | 42,00k | 4,42M | Derivative Exercise and Retained Stock | 105,17 | 65,48k | 178,88% |
| 2025-12-02 | Mr. Michel LagardeInsider | -62,00k | 29,61M | Derivative Exercise and Sale | 105,17 - 584,11 | 65,48k | - |
| 2025-12-02 | Mr. Thomas Bailey ShropshireSenior VP and General Counsel | -337,48 | 195,86k | Sale to Issuer | 580,37 | 5,08k | -6,23% |
| 2025-12-01 | Mr. Frederick M. LoweryInsider | -13,83k | 4,64M | Derivative Exercise and Sale | 253,99 - 597,68 | 12,19k | - |
| 2025-11-25 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -10,73k | 3,62M | Derivative Exercise and Sale | 253,99 - 600,00 | 15,57k | - |
| 2025-11-14 | Mr. Stephen WilliamsonInsider | -433,00 | 0,00 | Other Disposition | - | 44,56k | -0,96% |
| 2025-11-12 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -1,06k | 622,14k | Verkauf | 588,27 | 11,35k | -8,53% |
| 2025-11-13 | Mr. Michel LagardeInsider | -4,64k | 1,58M | Derivative Exercise and Sale | 253,99 - 594,42 | 23,48k | - |
| 2025-11-10 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -2,98k | 879,81k | Derivative Exercise and Sale | 253,99 - 580,00 | 21,15k | - |
| 2025-11-07 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -8,48k | 2,69M | Derivative Exercise and Sale | 253,99 - 571,67 | 12,40k | - |
| 2025-11-07 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -1,75k | 999,95k | Verkauf | 571,40 | 12,40k | -12,36% |
| 2025-10-24 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400,00 | 229,66k | Automatic Disposition | 574,15 | 21,15k | -1,86% |
| 2025-10-24 | Mr. Marc N. CasperChairman & CEO | -24,35k | 7,73M | Derivative Exercise and Sale | 253,99 - 575,02 | 128,85k | - |
| 2025-09-05 | Mr. Marc N. CasperChairman & CEO | -400,00 | 98,61k | Derivative Exercise and Sale | 253,99 - 501,01 | 128,85k | - |
| 2025-08-28 | Mr. Marc N. CasperChairman & CEO | -1,41k | 691,19k | Sale to Issuer | 489,74 | 128,85k | -1,08% |
| 2025-08-28 | Mr. Stephen WilliamsonInsider | -783,27 | 383,60k | Sale to Issuer | 489,74 | 44,99k | -1,71% |
| 2025-08-28 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -598,09 | 292,91k | Sale to Issuer | 489,74 | 15,57k | -3,70% |
| 2025-08-28 | Mr. Frederick M. LoweryInsider | -667,72 | 327,01k | Sale to Issuer | 489,74 | 12,19k | -5,20% |
| 2025-08-28 | Mr. Michel LagardeInsider | -961,20 | 470,74k | Sale to Issuer | 489,74 | 23,48k | -3,93% |
| 2025-08-29 | Mr. Joseph R. HolmesVP & CAO | -385,00 | 91,88k | Derivative Exercise and Sale | 253,99 - 492,63 | 1,96k | - |
| 2025-08-28 | Mr. Joseph R. HolmesVP & CAO | -36,98 | 18,11k | Sale to Issuer | 489,74 | 1,96k | -1,85% |
| 2025-08-28 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -814,70 | 398,99k | Sale to Issuer | 489,74 | 21,55k | -3,64% |
| 2025-08-28 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -328,78 | 161,02k | Sale to Issuer | 489,74 | 14,15k | -2,27% |
| 2025-08-22 | Mr. Marc N. CasperChairman & CEO | -10,00k | 2,47M | Derivative Exercise and Sale | 253,99 - 502,26 | 130,26k | - |
| 2025-08-19 | Mr. Marc N. CasperChairman & CEO | -496,00 | 122,07k | Derivative Exercise and Sale | 253,99 - 500,17 | 130,26k | - |
| 2025-08-06 | Mr. Marc N. CasperChairman & CEO | -18,00k | 3,58M | Derivative Exercise and Sale | 253,99 - 464,68 | 125,84k | - |
| 2025-07-25 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400,00 | 191,99k | Automatic Disposition | 479,98 | 22,37k | -1,76% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
